The caption reads something like "Down 130 lbs through ha
Clinical Indications and Who May Benefit Based on the preclinical literature and emerging clinical use patterns, BPC-157 is most commonly applied in the following areas: Tendon, ligament, and muscle injuries (sprains, partial tears, chronic tendinopathy) Post-surgical tissue healing and recovery acceleration Inflammatory bowel conditions (Crohns, ulcerative colitis, leaky gut syndromes) NSAID-induced gastric damage notably, BPC-157 counteracts aspirin- and ibuprofen-driven mucosal injury Neuropathy and nerve regeneration protocols Systemic inflammation and autoimmune flares Recovery from alcohol-related liver and gut damage It is also increasingly used as a component in broader peptide therapy protocols alongside BPC-157s companion compounds
The people pursuing this route, he said, are the ones who engage in the perhaps riskier practices of stacking multiple drugs, which may interact with one another in unknown ways
The FDAs Pharmacy Compounding Advisory Committee is scheduled to review seven of those peptides on July 23-24, 2026
Learn more about working with us
GLOW Blend peptide therapy may not be appropriate for every patient
